Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Short-term Investments (2016 - 2026)

Heron Therapeutics filings provide 12 years of Short-term Investments readings, the most recent being $18.7 million for Q1 2026.

  • On a quarterly basis, Short-term Investments fell 40.57% to $18.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $18.7 million, a 40.57% decrease, with the full-year FY2025 number at $18.0 million, down 46.29% from a year prior.
  • Short-term Investments hit $18.7 million in Q1 2026 for Heron Therapeutics, up from $18.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $71.3 million in Q3 2022 to a low of $12.4 million in Q3 2025.
  • Median Short-term Investments over the past 5 years was $34.9 million (2022), compared with a mean of $38.9 million.
  • Biggest five-year swings in Short-term Investments: skyrocketed 147.5% in 2024 and later tumbled 72.49% in 2025.
  • Heron Therapeutics' Short-term Investments stood at $69.5 million in 2022, then dropped by 25.55% to $51.7 million in 2023, then tumbled by 35.28% to $33.5 million in 2024, then tumbled by 46.29% to $18.0 million in 2025, then increased by 3.8% to $18.7 million in 2026.
  • The last three reported values for Short-term Investments were $18.7 million (Q1 2026), $18.0 million (Q4 2025), and $12.4 million (Q3 2025) per Business Quant data.